Harrow Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 01:31 am IST
Share
Harrow Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 33.47 million compared to USD 23.32 million a year ago. Net loss was USD 4.23 million compared to USD 6.24 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.23 a year ago.
For the six months, sales was USD 59.57 million compared to USD 45.44 million a year ago. Net loss was USD 10.87 million compared to USD 8.68 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.32 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.32 a year ago.
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.